Recombinant human c-KIT (D816V) (544-end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.
Catalog No. C06-12LG
Catalog No. | Pack Size | Price (USD) | |
---|---|---|---|
C06-12LG-05 | 5 ug | $226 | |
C06-12LG-10 | 10 ug | $325 | |
C06-12LG-BULK | BULK | Contact Us |
Overview:
c-KIT is a proto-oncogene and a type 3 transmembrane receptor for MGF (mast cell growth factor, also known as stem cell factor). c-KIT was first identified as the cellular homolog of the feline sarcoma viral oncogene v-kit. c-KIT together with its ligand regulates growth and activation of a variety of hemopoietic and non-hemopoietic cells. Mutations in c-KIT are associated with gastrointestinal stromal tumors, mast cell disease, acute myelogenous lukemia, and piebaldism. Recently, deregulation of the KIT receptor TK by the prevalent activation loop mutation D816V has served as a focal point in therapeutic strategies aimed at curbing neoplastic mast cell growth (2).
Gene Aliases:
PBT, SCFR, CD117
Genbank Number:
References:
1. Berger, S A.: Signaling pathways influencing SLF and c-kit-mediated survival and proliferation. Immunol Res. 2006;35(1-2):1-12.
2. Gotlib, J.: KIT mutations in mastocytosis and their potential as therapeutic targets. Immunol Allergy Clin North Am. 2006 Aug;26(3):575-92.
Specific Activity:
Sample Kinase Activity Plot. For specific information on a given lot, see related technical data sheet.
Purity:
Sample Purity Data. For specific information on a given lot, see related technical data sheet.
Storage, Stability and Shipping:
Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
Molecular Weight:
~73 kDa
Shraim AS et al., Developing and Characterization of Chemically modified RNA Aptamers for targeting Wild type and Mutated c-KIT Receptor Tyrosine Kinases. Journal of Medicinal Chemistry August 2019 10.1021/acs.jmedchem.9b00868
Krejci Pavel et al., NF449 Is a Novel Inhibitor of Fibroblast Growth Factor Receptor 3 (FGFR3) Signaling Active in Chondrocytes and Multiple Myeloma Cells Journal of Biological Chemistry July 2010 10.1074/jbc.M109.083626
Cancer, Inflammation, Neurobiology, Receptor Tyrosine Kinases
STAY CONNECTED
Fax: 1-604-232-4601